Bioxyne (ASX:BXN) signed an exclusive AU$7 million manufacturing and supply agreement with its existing customer, NectarTek Australia, according to a Thursday Australian bourse filing.

Its unit Breathe Life Sciences was named as the exclusive manufacturer of all NectarTek products for distribution in Australia, the UK, and Germany.

The agreement includes volume commitments which are expected to generate at least AU$7 million in revenue for Bioxyne in the fiscal year 2026.

The contract includes minimum order volumes of AU$3.6 million of pastilles, AU$2.5 million of packed flower products, AU$500,000 of vapes, and AU$500,000 of oral mucosal oils and other products.